國家衛生研究院 NHRI:Item 3990099045/15432
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 856558      線上人數 : 705
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/15432


    題名: Zoledronate as a preventative measure for bone loss following denosumab discontinuation: Results from a multi-institutional randomized controlled trial
    作者: Fu, SH;Lee, CC;Hung, CC;Li, CY;Wang, CY
    貢獻者: National Center for Geriatrics and Welfare Research
    摘要: Objective: The discontinuation of denosumab for the treatment ofosteoporosis can result in a rebound effect, characterized by a significant loss of bone mineral density (BMD) and an increased risk of vertebral fractures. This prospective multi-institutional randomized controlled trial aims to investigate whether zoledronate can prevent BMD loss after denosumab discontinuation in patients who have been receiving denosumab treatment for two or more years. Materials and methods: A total of 101 patients, including 95 females and 6 males with an average age of 70.9 years, were recruited for the study. Participants were stratified into 4 groups and received either regular denosumab therapy (group 1) or zoledronate treatment in the first year followed by on-time denosumab (group 2), on-time zoledronate (group 3), or drug holiday (group 4) in the second year. BMD and bone turnover markers (BTMs) were measured at baseline and annually thereafter. To facilitate the analysis of first-year results, we combined groups 2, 3, and 4 since all of them received zoledronate treatment in the first year, and compared them with group 1. Results: After one year, patients receiving continuous denosumab therapy had a significant increase in vertebral BMD compared to those receiving zoledronate treatment in the first year (2.07 ± 0.80% vs 0.64 ± 0.58%, p = 0.02). The difference in BMD loss was more pronounced in patients who had received denosumab for C 3 years compared to those treated for B 2.5 years (- 3.94 ± 1.60% vs. 0.45 ± 1.87%, p = 0.03). Low body weight was also identified as a risk factor for decreased BMD. Changes in P1NP were more sensitive to changes in bone metabolism indicators than CTX. Conclusions: The study results suggest that the duration of deno-sumab treatment affects the efficacy of sequential treatment with zoledronate, with significantly greater BMD loss observed in patients receiving denosumab for C 3 years compared to those treated for B 2.5 years. P1NP may be a leading indicator for deciding to add another zoledronate when monitoring BTMs. These findings align with the recommendation of the European Calcified Tissue Society.
    日期: 2023-07-21
    關聯: Aging Clinical and Experimental Research. 2023 Jul 21;35:S72.
    Link to: http://dx.doi.org/10.1007/s40520-023-02442-7
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1594-0667&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:001058500200074
    顯示於類別:[王貞予] 會議論文/會議摘要

    文件中的檔案:

    檔案 大小格式瀏覽次數
    ISI001058500200074.pdf63KbAdobe PDF39檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋